Caris Life Sciences, Inc. (CAI) intrinsic value & 10-year financials
Caris Life Sciences, Inc. (CAI) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue grew 62.9% a year to $812.0M, with an average return on invested capital of 8.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $30.56
- Market cap
- $5.1B
- Revenue (FY2025)
- $812.0M
- Revenue growth (4-yr CAGR)
- 62.9%
- ROIC (10-yr avg)
- 8.0%
- Free cash flow (FY2025)
- $66.9M
CAI 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $812.0M | -$68.1M | -$3.22 | $66.9M | 5.6% | -4.6% |
| FY2024 | $412.3M | -$281.9M | -$10.66 | -$253.6M | -62.4% | 12.0% |
| FY2023 | $306.1M | -$341.4M | -$13.24 | -$298.4M | -104.4% | 16.6% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Caris Life Sciences, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Caris Life Sciences, Inc. has historically struggled to out-earn its cost of capital, averaging just 3.7% ROIC.
Caris Life Sciences, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Caris Life Sciences, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-106.95 per share.